After exiting Chapter 11 protection for which it had filed in 2020, Akorn has announced that it will commence a review of strategic alternatives for its consumer health business. According to the company, which is now operating as a private entity under the legal name, Akorn Operating Company LLC, “this strategic review is a reflection of management’s continued focus on its prescription generic and branded drug portfolio.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?